These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 25656744)
21. Metronomic chemotherapy: new rationale for new directions. Pasquier E; Kavallaris M; André N Nat Rev Clin Oncol; 2010 Aug; 7(8):455-65. PubMed ID: 20531380 [TBL] [Abstract][Full Text] [Related]
22. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice. Shi S; Tao L; Song H; Chen L; Huang G APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells. Ferdous T; Harada K; Kin T; Harada T; Ueyama Y Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365 [TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic scheduling of lower dose cancer chemotherapy. Gately S; Kerbel R Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902 [TBL] [Abstract][Full Text] [Related]
25. Metronomic scheduling: the future of chemotherapy? Gasparini G Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel. Akiyama K; Maishi N; Ohga N; Hida Y; Ohba Y; Alam MT; Kawamoto T; Ohmura H; Yamada K; Torii C; Shindoh M; Hida K Am J Pathol; 2015 Feb; 185(2):572-80. PubMed ID: 25498238 [TBL] [Abstract][Full Text] [Related]
28. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Loven D; Hasnis E; Bertolini F; Shaked Y Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084 [TBL] [Abstract][Full Text] [Related]
29. Dynamics and control of a mathematical model for metronomic chemotherapy. Ledzewicz U; Amini B; Schättler H Math Biosci Eng; 2015 Dec; 12(6):1257-75. PubMed ID: 26775862 [TBL] [Abstract][Full Text] [Related]
31. Resistance to metronomic chemotherapy and ways to overcome it. Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819 [TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Samuel DP; Wen PY; Kieran MW Expert Opin Investig Drugs; 2009 Jul; 18(7):973-83. PubMed ID: 19548852 [TBL] [Abstract][Full Text] [Related]
33. Metronomic chemotherapy: teaching old drugs new tricks? Vogelzang N Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217 [No Abstract] [Full Text] [Related]
34. Role of vascular normalization in benefit from metronomic chemotherapy. Mpekris F; Baish JW; Stylianopoulos T; Jain RK Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262 [TBL] [Abstract][Full Text] [Related]
35. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules. Banchi M; Cox MC; Bocci G Cancer Lett; 2024 Jun; 591():216900. PubMed ID: 38636896 [TBL] [Abstract][Full Text] [Related]
36. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
37. Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Mahmud F; Jeon OC; Alam F; Maharjan R; Choi JU; Park J; Lee S; Park JW; Lee DS; Byun Y J Control Release; 2018 Aug; 284():160-170. PubMed ID: 29908222 [TBL] [Abstract][Full Text] [Related]
38. Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Noronha V; Patil VM; Joshi A; Chougule A; Banavali S; Prabhash K Cancer Lett; 2017 Aug; 400():267-275. PubMed ID: 28109908 [TBL] [Abstract][Full Text] [Related]
39. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. Gille J; Spieth K; Kaufmann R J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746 [TBL] [Abstract][Full Text] [Related]
40. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]